[
  {
    "objectID": "career/index.html",
    "href": "career/index.html",
    "title": "Immunological education and career support",
    "section": "",
    "text": "Immunological education and career support\n\nClinician Scientist Program INDEEP\n\nFollowing a highly competitive selection process, a new Clinician Scientist program is funded by the DFG. “Inflammation-Driven Diseases Programme (INDEEP): Inflammation as a Disease Driver and Therapeutic Target” with spokesperson Prof. Evelyn Ullrich and deputy Prof. Sandra Ciesek will start in mid-2023 to train interdisciplinary Clincian Scientists at the Department of Medicine. Further information\n\nClinical Training in Immunology\n\nSince the amendment of the WBO 2020, it is possible to acquire additional training in immunology. This comprises, in addition to a specialist competence, the specialist clinical diagnosis and therapy of immunodeficiencies and immunodysregulation syndromes including immunodiagnostic methods.\nFurther information can be found on the German-language webpage of the LÄKH.\n\nTraining as specialist immunologist DGfI\n\nThe German Society for Immunology (DGfI) has granted the Department of Pediatrics and Adolescent Medicine of the Goethe University Frankfurt the institute authorization for further training as a specialist immunologist DGfI.\nFurther information can be found on the German-language webpage of the DGfI."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Ullrich Lab",
    "section": "",
    "text": "EXPERIMENTAL IMMUNOLOGY\nAND CELL THERAPY\n\n The Experimental Immunology and Cell Therapy Division is headed by Evelyn Ullrich, MD, Professor of Cellular Immunology, and includes preclinical and translational research projects as well as education and training in the field of immunology .Preclinical research projects focus on the investigation of complex interactions in malignant diseases, immunodeficiencies as well as in stem cell transplantation and infectious complications. Our projects include molecular and functional characterization of cellular components of the immune system with emphasis on subsets of T cells, natural killer (NK) cells, cytokine-induced killer (CIK) cells and innate lymphoid cells (ILCs). Transcriptome and proteome analyses at single cell level combined with advanced model systems for live cell imaging provide in-depth understanding of molecular and Translational research aims to develop innovative cell-based immunotherapies. Viral and non-viral technologies for the generation of CAR engineered immune cell products are optimized in a broad range of in vitro/in vivo models. The foundations are laid for GMP-compliant manufacturing and clinical application of genetically modified cell therapies and combinatorial treatment concepts.Artificial intelligence (AI) and machine learning (ML) technologies for data analysis, design and prediction will be applied to tailor immune cell therapies to specific needs and patients, thereby leading to the next level of development and translation of personalized medicine. \n\nNews\n See all news\n\n\n\n\n\n\n\n\n\n\n\nJuni 2025\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nJuli 2024\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nApril 2024\n\n\n\n\n\n\n\n\nNo matching items\n\n\nEvents\n See all events\n\n\n\n\n\n\n\n16th-18th Oktober 2024Lyon\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n6th September 2024Freiburg\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n28th-30th August 2024Frankfurt\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "index.html#contact",
    "href": "index.html#contact",
    "title": "Ullrich Lab",
    "section": "Contact",
    "text": "Contact\n\nHEAD\n\n\nProf. Dr. med. Evelyn Ullrich\n\n\n\n\n\n evelyn | ullrichlab.de\n\n\n +49 69 6301 83000\n\n\n\n \n\n\n \n\n\nSCIENTIFIC PROJECT COORDINATION\n\n\nDr.rer.nat. Thorsten Diegisser\n\n\n diegisser | med.uni-frankfurt.de\n\n\n +49 151 150 96319\n\n\n \n\n\nLABORATORY\n\n\nFranziska Ganß\n\n\n franziska.ganss | med.uni-frankfurt.de\n\n\n +49 69 6301 80651 (Office)\n\n\n +49 69 6301 80648 (Laboratory)\n\n\n +49 151 171 90472"
  },
  {
    "objectID": "contact/index.html",
    "href": "contact/index.html",
    "title": "Contact",
    "section": "",
    "text": "Contact\n\n\nADDRESS\n\nUllrich Lab\nLaboratory for Experimental Immunology & Cell Therapy\nDepartment of Pediatrics, Goethe University\nTheodor-Stern-Kai 7\nBuilding 32 E, 2nd Floor\n60590 Frankfurt am Main\n\n\n\n\nHEAD\n\n\nProf. Dr. med. Evelyn Ullrich\n\n\n\nUniversity Professorship “Cellular Immunology”\n\n\nConsulting physician for internal medicine and immunology\n\n\nAdditional certification Immunology Specialist / Immunologist DGfI\n\n\n evelyn | ullrichlab.de\n\n\n +49 69 6301 83000\n\n\n ullrich_lab\n\n\n \n\n\nLABORATORY\n\n\nFranziska Ganß\n\n\nLab Management\n\n\n franziska.ganss | med.uni-frankfurt.de\n\n\n +49 69 6301 80648\n\n\n +49 151 171 90472\n\n\n\n\n\nSCIENTIFIC PROJECT COORDINATION\n\n\nDr. rer. nat. Thorsten Diegisser\n\n\nScientific Project Coordinator\n\n\nWorking hours: Monday, Wednesday, Thursday 08:00-12:00\n\n\n diegisser | med.uni-frankfurt.de\n\n\n +49 151 150 96319\n\n\n \n\n\nCAREER DEVELOPMENT\n\n\nStephanie Faber\n\n\nINDEEP Clinician Scientist Program\n\n\n faber | med.uni-frankfurt.de\n\n\n +49 151 171 92247"
  },
  {
    "objectID": "impressum.html",
    "href": "impressum.html",
    "title": "Impressum",
    "section": "",
    "text": "Impressum\nAnbieter der Internetpräsenz\nProf. Dr. med. Evelyn Ullrich, Theodor-Stern-Kai 7, 60590 Frankfurt am Main\nKontakt: Prof. Dr. med. Evelyn Ullrich\nTelefon: +49 69 6301 83000\n\n\nStreitschlichtung\nDie Europäische Kommission stellt eine Plattform zur Online-Streitbeilegung (OS) bereit: https://ec.europa.eu/consumers/odr. Unsere E-Mail-Adresse finden Sie oben im Impressum.\nWir sind nicht bereit oder verpflichtet, an Streitbeilegungsverfahren vor einer Verbraucherschlichtungsstelle teilzunehmen.\n\n\nHaftung für Inhalte\nAls Diensteanbieter sind wir gemäß § 7 Abs.1 TMG für eigene Inhalte auf diesen Seiten nach den allgemeinen Gesetzen verantwortlich. Nach §§ 8 bis 10 TMG sind wir als Diensteanbieter jedoch nicht verpflichtet, übermittelte oder gespeicherte fremde Informationen zu überwachen oder nach Umständen zu forschen, die auf eine rechtswidrige Tätigkeit hinweisen.\nVerpflichtungen zur Entfernung oder Sperrung der Nutzung von Informationen nach den allgemeinen Gesetzen bleiben hiervon unberührt. Eine diesbezügliche Haftung ist jedoch erst ab dem Zeitpunkt der Kenntnis einer konkreten Rechtsverletzung möglich. Bei Bekanntwerden von entsprechenden Rechtsverletzungen werden wir diese Inhalte umgehend entfernen.\n\n\nHaftung für Links\nUnser Angebot enthält Links zu externen Websites Dritter, auf deren Inhalte wir keinen Einfluss haben. Deshalb können wir für diese fremden Inhalte auch keine Gewähr übernehmen. Für die Inhalte der verlinkten Seiten ist stets der jeweilige Anbieter oder Betreiber der Seiten verantwortlich. Die verlinkten Seiten wurden zum Zeitpunkt der Verlinkung auf mögliche Rechtsverstöße überprüft. Rechtswidrige Inhalte waren zum Zeitpunkt der Verlinkung nicht erkennbar.\nEine permanente inhaltliche Kontrolle der verlinkten Seiten ist jedoch ohne konkrete Anhaltspunkte einer Rechtsverletzung nicht zumutbar. Bei Bekanntwerden von Rechtsverletzungen werden wir derartige Links umgehend entfernen.\n\n\nUrheberrecht\nDie durch die Seitenbetreiber erstellten Inhalte und Werke auf diesen Seiten unterliegen dem deutschen Urheberrecht. Die Vervielfältigung, Bearbeitung, Verbreitung und jede Art der Verwertung außerhalb der Grenzen des Urheberrechtes bedürfen der schriftlichen Zustimmung des jeweiligen Autors bzw. Erstellers. Downloads und Kopien dieser Seite sind nur für den privaten, nicht kommerziellen Gebrauch gestattet.\nSoweit die Inhalte auf dieser Seite nicht vom Betreiber erstellt wurden, werden die Urheberrechte Dritter beachtet. Insbesondere werden Inhalte Dritter als solche gekennzeichnet. Sollten Sie trotzdem auf eine Urheberrechtsverletzung aufmerksam werden, bitten wir um einen entsprechenden Hinweis. Bei Bekanntwerden von Rechtsverletzungen werden wir derartige Inhalte umgehend entfernen.\n\n\nDatenschutz\nDie Nutzung dieser Webseite ist in der Regel ohne Angabe personenbezogener Daten möglich."
  },
  {
    "objectID": "projects/index.html",
    "href": "projects/index.html",
    "title": "PROJECTS",
    "section": "",
    "text": "Research Projects and Networks\n\n\n\nGerman Cancer Aid – CAR FACTORY\n\nThe German Cancer Aid (Deutsche Krebshilfe) has set up a funding priority program to strengthen “preclinical drug development” at universities. The aim is to create a Germany-wide network that brings together expertise from biology, medicine, pharmaceutical chemistry, pharmacology and immunotherapy.\nIn this context, German Cancer Aid funds the Germany-wide research network “CAR FACTORY” lead by the spokespersons Prof. Michael Hudecek (Würzburg) and Prof. Evelyn Ullrich (Frankfurt); further partner sites involved in the CAR FACTORY are the University of Freiburg, the Paul Ehrlich Institute in Langen and the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig.\n\nSFB/CRC 1292\n\nWithin the framework of the CRC 1292 „Targeting convergent mechanisms of inefficient immunity in tumors and chronic infections“, we investigate the development of innovative immunotherapy of solid tumors as well as AML in cooperation projects with Prof. S. Fulda and Prof. Dr. M. Kühn.\n\nDKTK INNOVATION 2022 - “Cancer Immunotherapy, CI”\n\nWithin the framework of the DKTK Joint Funding program INNOVATION 2022, we address the translational development of a combination therapy for the treatment of acute myeloid leukemia. Coordinated by Prof. Evelyn Ullrich, Frankfurt, the DKTK sites Freiburg, Tübingen, Heidelberg and Berlin as well as the Paul Ehrlich Institute in Langen are scientific and clinical co-investigators of this program.\nThe long-term goal of the DKTK Cancer Immunotherapy Program is to fight cancer using the power of the immune system.\n\nGerman Cancer Aid – Translational Oncology\n\nIn an innovative collaborative scientific project led by Prof. Evelyn Ullrich, the translational focus is on the development and production of a CAR-NK cell therapy for the treatment of acute myleoid leukemia. Participating research groups and university hospitals are located in Frankfurt, Heidelberg-Mannheim, Tübingen, Erlangen, Leipzig and at the Fraunhofer Institute for Cell Therapy and Immunology IZI.\n\nPandemic Network Hesse - Consortium for the Study of the Immune Response to SARS-CoV-2\n\nWithin the framework of various studies, the immune response to SARS-CoV-2 after SARS-CoV-2 vaccination in patients with hematological diseases will be investigated in comparison to an age-matched control cohort. The focus of the project is to analyze a large cohort of patients with multiple myeloma as an example of a malignant disease with significant impairment of the immune system. The analyses of the healthy control cohort of elderly patients will be performed in close collaboration with the Medical Clinic II, Virology, Infectiology and the UCT Frankfurt - Marburg. The project is realized by funding of Prof. Ullrich as expert for immunology in the Pandemic Network Hessen by the HMWK and also supported by the Goethe Corona Fonds of Goethe University Frankfurt.\n\n\n\nMethods\n\n\n\nCellular Immunotherapy\n\n\nViral and non-viral genetic modification of immune and tumor cells using CRISPR/Cas9, Sleeping Beauty and viral vectors (LV/αRV)\nCharacterization of T cell, NK cell, and ILC subpopulations and immune cell products\nMolecular biological analyses and protein biochemistry\nOptimization of immune cell expansion and immunomodulation\nDevelopment of innovative CAR immune cell products\nPreparation of GMP manufacturing processes\nClinical studies in the field of cellular immunotherapy\n\n\nOptical Imaging Technology\n\n\nConfocal Live Cell Imaging\nFlow cytometry and cell sorting (FACS)\nIn vivo bioluminescence and fluorescence imaging facility\n\n\nImmunodiagnostics\n\n\nImmune reconstitution after stem cell transplantation\nFunctional immune diagnostics\nTranscriptome and proteome analyses on single cell level\nBiomarker and microbiome analyses\n\n\n\n\nPublications\n\n\nLink to PubMed of Prof. Dr. Evelyn Ullrich\n\n\n\nSelected Awards\n\n\n\nAward by the Gutermuth Foundation 2023\n\nScience award to Prof. Evelyn Ullrich for her successful activities in the field of cell therapy development. Further information\n\nAward by the German Society for Gene Therapy (DG-GT)\n\nThe recent work on CRISPR/Cas9-based gene editing of NK cells by the research group of Evelyn Ullrich, Frankfurt, and Toni Cathomen, Freiburg, was awarded “Paper of the Quarter 02/22”. Further information\n\nGilead-Research Award for CAR-NK cell therapy\n\nThis Gilead award supports the promising and innovative research project of the Ullrich team. An independent panel of experts selected the best projects from numerous applications and provided the award winners with a total of 600,000 euros in funding. Further information\n\nAwards at the ASH, DGHO and EBMT Annual Meetings\n\n\n“DGHO Best Abstract Award 2023” for Evelyn Ullrich & team\n“EBMT Best Young Oral Abstract Award” 2023 for Julia Campe (PhD-student Ullrich Lab)\n“ASH Abstract Achievement Award” 2022 at the Annual Meeting of the American Society of Hematology for Julius Enßle (Clinician Scientist in the SARS-CoV2 research project).\n“Springer Nature Poster Award” (Best Basic Science Poster Award) 2021 and “Best Young Abstract Award” 2021 at the Annual Meeting of the European Bone Marrow Transplantation Society (EBMT) for Tobias Bexte (Medical Doctoral Student Ullrich Lab).\n“Best Young Abstract Award” 2016 at the Annual Meeting of the European Society for Bone Marrow Transplantation (EBMT) for Sara Tognarelli (Postdoctoral Researcher Ullrich Lab).\n\n\n\n\nFunding"
  },
  {
    "objectID": "team/index.html",
    "href": "team/index.html",
    "title": "TEAM",
    "section": "",
    "text": "TEAM\n\n\n\n \n\n\n\n\nf.l.t.r.: Philipp Wendel, Nawid Albinger, Jan Habermann, Tobias Bexte, Lisa Marie Reindl, Evelyn Ullrich, Julia Campe, Franziska Ganß, Alina Moter, Thorsten Diegisser, Katja Stein, Fenja Gierschek, Alice Born, Elisa Dollberg (2022).\nNot on the photo (in alphabetical order): Leon Buchinger, Janne Hauck, Lennart Krähl, Lida Jalili, Sophia Thul."
  },
  {
    "objectID": "news/hessenschau.html",
    "href": "news/hessenschau.html",
    "title": "Wenn die eigenen Zellen den Krebs besiegen",
    "section": "",
    "text": "Ullrich Lab in the series “Research in Hessen” - with the topic of cell therapy - on 9 April 2024: CAR-T-Zell-Therapie (hessenschau.de)"
  },
  {
    "objectID": "events/fcc.html",
    "href": "events/fcc.html",
    "title": "Frankfurt Cancer Conference",
    "section": "",
    "text": "The Frankfurt Cancer Conference is a three-day on-site meeting of internationally leading cancer researchers as well as junior scientists and clinical oncologists. The main theme of the conference in 2024 is “Targeting the tumor-host interface”.\nThe ongoing translational research activities of the University Cancer Center (UCT) Frankfurt, the German Cancer Consortium (DKTK) in Frankfurt/Mainz and the Frankfurt Cancer Institute (FCI) provide the framework for the conference. International, national and local research activities will be presented."
  },
  {
    "objectID": "events/symposium_int_onc.html",
    "href": "events/symposium_int_onc.html",
    "title": "Symposium “Intelligent Oncology – The Potential Of AI To Control Cancer“",
    "section": "",
    "text": "Bringing together experts from various disciplines to explore the latest advances in AI-assisted cancer research. The Symposium “Intelligent Oncology – The Potential Of AI To Control Cancer“ promotes collaboration between researchers, physicians, industry leaders, and other visionaries in the field. By sharing knowledge and expertise, we aim to discover new ways to control cancer through the power of AI."
  },
  {
    "objectID": "events/symposium_NK_ILC.html",
    "href": "events/symposium_NK_ILC.html",
    "title": "NK/ILC Symposium 2024",
    "section": "",
    "text": "The NK/ILC Symposium traditionally takes place in Germany each year, initiated by the Study Group “NK cells and ILCs” of the German Society for Immunology (DGFI).\nThe meeting will bring together experts in innate lymphocyte biology, and cover the latest emerging concepts in the field, their clinical translation, and the application of cutting-edge high-resolution technologies. The meeting will host researchers, industrials, and clinicians with a common interest in NK cells and ILCs. It will discuss how the current understanding of the development and biology of NKs and ILCs might enable development of next-generation therapies in cancer and chronic infections."
  },
  {
    "objectID": "news/news/hessenschau.html",
    "href": "news/news/hessenschau.html",
    "title": "Wenn die eigenen Zellen den Krebs besiegen",
    "section": "",
    "text": "September 2024\n\nUllrich Lab in the series “Research in Hessen” - with the topic of cell therapy - on 9 April 2024: CAR-T-Zell-Therapie (hessenschau.de)"
  },
  {
    "objectID": "events/events/symposium_int_onc.html",
    "href": "events/events/symposium_int_onc.html",
    "title": "Symposium “Intelligent Oncology – The Potential Of AI To Control Cancer“",
    "section": "",
    "text": "Bringing together experts from various disciplines to explore the latest advances in AI-assisted cancer research. The Symposium “Intelligent Oncology – The Potential Of AI To Control Cancer“ promotes collaboration between researchers, physicians, industry leaders, and other visionaries in the field. By sharing knowledge and expertise, we aim to discover new ways to control cancer through the power of AI.\n\n\n 6th September 2024\n\n\n\n Freiburg"
  },
  {
    "objectID": "events/events/symposium_NK_ILC.html",
    "href": "events/events/symposium_NK_ILC.html",
    "title": "NK/ILC Symposium 2024",
    "section": "",
    "text": "The NK/ILC Symposium traditionally takes place in Germany each year, initiated by the Study Group “NK cells and ILCs” of the German Society for Immunology (DGFI).\nThe meeting will bring together experts in innate lymphocyte biology, and cover the latest emerging concepts in the field, their clinical translation, and the application of cutting-edge high-resolution technologies. The meeting will host researchers, industrials, and clinicians with a common interest in NK cells and ILCs. It will discuss how the current understanding of the development and biology of NKs and ILCs might enable development of next-generation therapies in cancer and chronic infections.\n\n\n 16th to 18th October 2024\n\n\n\n Lyon"
  },
  {
    "objectID": "events/events/fcc.html",
    "href": "events/events/fcc.html",
    "title": "Frankfurt Cancer Conference",
    "section": "",
    "text": "The Frankfurt Cancer Conference is a three-day on-site meeting of internationally leading cancer researchers as well as junior scientists and clinical oncologists. The main theme of the conference in 2024 is “Targeting the tumor-host interface”.\nThe ongoing translational research activities of the University Cancer Center (UCT) Frankfurt, the German Cancer Consortium (DKTK) in Frankfurt/Mainz and the Frankfurt Cancer Institute (FCI) provide the framework for the conference. International, national and local research activities will be presented.\n\n\n 28th to 30th October 2024\n\n\n\n Frankfurt"
  },
  {
    "objectID": "events/index.html",
    "href": "events/index.html",
    "title": "Ullrich Lab",
    "section": "",
    "text": "Events\n\n\n\n\n\n\n\n16th-18th Oktober 2024Lyon\n\n\n\n\n\nNK/ILC Symposium 2024\n\n\n\n\n\n\n\n\n\n\n\n\n6th September 2024Freiburg\n\n\n\n\n\nSymposium “Intelligent Oncology – The Potential Of AI To Control Cancer“\n\n\n\n\n\n\n\n\n\n\n\n\n28th-30th August 2024Frankfurt\n\n\n\n\n\nFrankfurt Cancer Conference\n\n\n\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "news/news/award2024.html",
    "href": "news/news/award2024.html",
    "title": "Paper Award by the German Society for Gene Therapy (DG-GT)",
    "section": "",
    "text": "July 2024\n\nThe recent work by Tobias Bexte on “Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors“ from the research group of Evelyn Ullrich, Frankfurt, was awarded “Paper of the Quarter Q2/24”."
  },
  {
    "objectID": "news/index.html",
    "href": "news/index.html",
    "title": "Ullrich Lab",
    "section": "",
    "text": "News\n\n\n\n\n\n\n\n\n\n\n\nNK & ILC Symposium 2026 in Freiburg\n\nJuni 2025\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPaper Award by the German Society for Gene Therapy (DG-GT)\n\nJuli 2024\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWenn die eigenen Zellen den Krebs besiegen\n\nApril 2024\n\n\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "news/news/NK_ILC_Symposium_2026.html",
    "href": "news/news/NK_ILC_Symposium_2026.html",
    "title": "NK & ILC Symposium 2026 in Freiburg",
    "section": "",
    "text": "June 2025\n\nWe are delighted to announce that we are organizing the NK & ILC Symposium 2026 on March 11-13, in Freiburg on behalf of the NK & ILC Study Group of the German Society of Immunology (DGfI) NK & ILC Study Group. With Evelyn Ulrich and Susana Minguet as Co-Chairs, this symposium will bring together experts in NK, ILC and also γδ T cells for the first time. We look forward to welcome you in the beautiful city of Freiburg for three days full of exciting science."
  },
  {
    "objectID": "events/events/NK_ILC_Symposium_Freiburg.html",
    "href": "events/events/NK_ILC_Symposium_Freiburg.html",
    "title": "NK & ILC Symposium FReiburg 2026",
    "section": "",
    "text": "The Frankfurt Cancer Conference is a three-day on-site meeting of internationally leading cancer researchers as well as junior scientists and clinical oncologists. The main theme of the conference in 2024 is “Targeting the tumor-host interface”.\nThe ongoing translational research activities of the University Cancer Center (UCT) Frankfurt, the German Cancer Consortium (DKTK) in Frankfurt/Mainz and the Frankfurt Cancer Institute (FCI) provide the framework for the conference. International, national and local research activities will be presented.\n\n\n 11th to 13th October 2026\n\n\n\n Freiburg"
  }
]